Drug Profile
Research programme: heat shock protein modulators - Biogen
Latest Information Update: 28 Sep 2023
Price :
$50
*
At a glance
- Originator University of Kansas
- Developer Biogen
- Class Small molecules
- Mechanism of Action HSP70 heat-shock protein modulators; HSP90 heat-shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Demyelinating disorders; Diabetic neuropathies